Video

Provocative Questions in Prostate Cancer VL

Search

Should Checkpoint Inhibitors Ever Be Used Outside of a Clinical Trial in Prostate Cancer - James Gulley Details In a comprehensive discussion led by Charles Ryan, James Gulley delves into the role of genomic testing and immunotherapy in treating prostate cancer. Dr. Gulley emphasizes the importance of personalized treatment, highlighting studies that identify specific genomic markers like homologous recombination deficiency and mismatch repair deficiency. These markers can guide the use of targeted therapie...
Can We Make Any More Progress Targeting the Androgen - Androgen Receptor Interaction - Nima Sharifi Details In a discussion between Charles Ryan and Nima Sharifi, the focus is on the complexities of targeting the androgen-androgen receptor interaction in prostate cancer. Dr. Sharifi categorizes tumors into three types: androgen-dependent, castration-resistant via androgen agnostic pathways, and those resistant through androgen and androgen receptor agnostic mechanisms. He introduces the gene HSD3B1, whi...
How Can We Leverage Our Understanding of the Tumor Microenvironment to Improve Systemic Therapy? - Kenneth Pienta Details In a comprehensive discussion between Charles Ryan and Kenneth Pienta, the focus is on the tumor microenvironment in prostate cancer. Dr. Pienta describes the tumor microenvironment as an ecological system, emphasizing the interactions between cancer cells and various other cell types. He argues that current treatments, including immunotherapies, must be understood in the context of this microenvi...